Mineralys Therapeutics Inc. (MLYS): Price and Financial Metrics

Mineralys Therapeutics Inc. (MLYS): $10.85

0.51 (-4.49%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

MLYS Price/Volume Stats

Current price $10.85 52-week high $17.70
Prev. close $11.36 52-week low $5.85
Day low $10.70 Volume 3,717
Day high $11.13 Avg. volume 156,121
50-day MA $13.40 Dividend yield N/A
200-day MA $11.05 Market Cap 538.50M

MLYS Stock Price Chart Interactive Chart >



MLYS Latest News Stream


Event/Time News Detail
Loading, please wait...

MLYS Latest Social Stream


Loading social stream, please wait...

View Full MLYS Social Stream

Latest MLYS News From Around the Web

Below are the latest news stories about MINERALYS THERAPEUTICS INC that investors may wish to consider to help them evaluate MLYS as an investment opportunity.

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HT

Yahoo | December 21, 2023

Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | November 27, 2023

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions]. It is now my pleasure to introduce your host, Dan Ferry, of LifeSci Advisors. Please go ahead. Dan Ferry: Thank you, operator. Good afternoon, […]

Yahoo | November 12, 2023

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone – – Excess aldosterone in patients with visceral obesity defines a unique hypertensive endotype with potential for an enhanced response to aldosterone-targeted therapy with lorundrostat – – Early identification and intervention with lorundrostat may result in improved clinical outcomes for obese patients with uncontrolled

Yahoo | November 11, 2023

Mineralys Therapeutics to Participate in Three Upcoming Conferences

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London

Yahoo | November 9, 2023

Read More 'MLYS' Stories Here

MLYS Price Returns

1-mo -15.50%
3-mo 5.34%
6-mo 42.76%
1-year -15.63%
3-year N/A
5-year N/A
YTD 26.16%
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!